cardiovascular

News

Boehringer backs NHS trust programme for diabetics

An alliance between German pharma group Boehringer Ingelheim and an NHS trust in the UK has been launched with the aim of reducing recurring heart attacks in people with d

News

Anthos hails win over Xarelto with novel anticoagulant

Anthos Therapeutics says a phase 2b trial of its factor XI inhibitor anticoagulant abelacimab has been stopped early due to an “overwhelming” reduction in bleeding complic

News

Dutch R&D agency spins out health wearables company

The Netherlands’ R&D agency TNO has launched a digital health company – AIKON Health – that will focus on the development of wearable devices that will be used to moni

News

Lift for Roche as Alnylam drug lowers blood pressure

Just weeks after wagering $310 million upfront on the rights to Alnylam's hypertension therapy zilebesiran on the strength of phase 1 data, Roche has been rewarded by a po

News

J&J pulls out of Idorsia deal for hypertension drug

Idorsia has lost Johnson & Johnson's Janssen Biotech unit as the partner for its aprocitentan candidate for resistant hypertension, following a likely delay in the FDA

News

HDL Therapeutics eyes public listing in $480m SPAC deal

US medical device company HDL Therapeutics is aiming to list on the Nasdaq via a merger with Swiftmerge Acquisition, a special purpose acquisition company (SPAC).

Boehringer backs NHS trust programme for diabetics

Anthos hails win over Xarelto with novel anticoagulant

Dutch R&D agency spins out health wearables company

Lift for Roche as Alnylam drug lowers blood pressure

J&J pulls out of Idorsia deal for hypertension drug

HDL Therapeutics eyes public listing in $480m SPAC deal

NHS use of digital cardiac rehab tools endorsed

How to meet your physicians where they are online

cardiovascular

Editor's Picks